Oxford BioMedica will lead a consortium of partners in a £2 million two-year collaboration focussed on gene and cell therapy manufacturing.
The collaboration – part funded by Britain’s innovated agency, Innovate UK – incorporates the Cell and Gene Therapy Catapult; Stratophase and Synthace.
The project aims to deliver tangible benefits to patients by shortening the time-to-clinic and time-to-market as well as to improve the cost and access of bringing novel gene and cell therapies to patients.
Together, the consortium will explore and apply novel advanced technologies to further evolve Oxford BioMedica’s proprietary suspension LentiVector platform.
Each partner in the collaboration holds proprietary technology and know-how that can be used to develop an innovative approach to viral vector manufacturing.
Oxford BioMedica CEO John Dawson said: “Cell and gene therapies offer unprecedented promise for the cure, treatment or long term management of disease and we are delighted that this consortium has been awarded funding from Innovate UK that will help to keep Oxford BioMedica, our partners and the UK, at the forefront of innovation in industrial viral vector manufacturing.”